India Pharma Outlook Team | Wednesday, 18 June 2025
The Department of Pharmaceuticals (DoP) has clarified that they extended the application period for the most recent PLI scheme round for bulk drugs, from June 14 to July 4, 2025.
The current round is evaluating the selection for up to 25 manufacturers for a total of 11 critical products including KSMs, DIs and APIs that were completely or partially unsubscribed.
Selected products for this round include six fermentation based products, erythromycin thiocyanate, neomycin, gentamicin, clindamycin, streptomycin, and tetracycline, and five chemical synthesis based products, 2-methyl-5-nitroimidazole, dicyandiamide, ciprofloxacin, diclofenac sodium, and 1,1 cyclohexane diacetic acid. All applicants are required to demonstrate minimum production capacity. Furthermore, all selected manufacturers must not exceed the limits of the incentive, and also produce within the applicable timeframes - until FY 2027-28 for chemical synthesis and, FY 2028-29 for fermentation products.
Also Read: Unlocking India's Innovation Potential in Pharma
Applicants who had previously submitted an application for products under this scheme but then withdrew or were disqualified - are not eligible to reapply for the same products. The DoP has approved 48 of 249 applications overall since the start of the scheme in March 2020. Notable projects include the Penicillin G facility in Andhra Pradesh, which cost ?1,910 crore, and the Clavulanic Acid project in Himachal Pradesh which cost ?450 crore. Both projects meet the scheme's objectives of reducing import dependence and developing the manufacturing base for pharmaceuticals in India.
, CDSCO.jpg)
